Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eblasakimab - ASLAN Pharmaceuticals

Drug Profile

Eblasakimab - ASLAN Pharmaceuticals

Alternative Names: ASLAN 004; CSL 334; IL-13R - Merck; IL-13Rα1 project; MK 6105

Latest Information Update: 19 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; Zenyth Therapeutics
  • Developer ASLAN Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors; Interleukin-13 receptor alpha1 subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Preclinical Chronic obstructive pulmonary disease
  • No development reported Asthma

Most Recent Events

  • 07 May 2024 Updated interim efficacy and adverse events data from a phase IIb TREK-DX trial in Atopic dermatitis released by ASLAN Pharmaceuticals
  • 22 Apr 2024 Interim efficacy data from a phase IIb TREK-DX trial in Atopic dermatitis released by ASLAN Pharmaceuticals
  • 12 Apr 2024 Efficacy data from a phase IIb TREK-AD trial in Atopic dermatitis released by ASLAN Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top